Polymer conjugation to biologics is of key interest to the pharmaceutical industry for the
development of potent and long acting biotherapeutics, with poly (ethylene glycol)(PEG) …

Since several decades, PEGylation is known to be the clinical standard to enhance
pharmacokinetics of biotherapeutics. In this study, we introduce polyglycerol (PG) of different …

With more than 20 Food and Drug Administration (FDA)-approved poly (ethylene
glycol)(PEG) modified drugs on the market, PEG is the gold standard polymer in …

Highlights•Limitations of conjugating poly (ethylene glycol) to proteins and peptides have
become increasingly apparent.•Various polymers have shown promise as PEG …

Although PEGylation is a potential approach to prolong the half-lives and reduce the dosing
frequency of therapeutic proteins, conjugation behaviors of polymer have pivotal effects on …

With the rapid advances in the field of biotechnology during the last decade, many peptides
and proteins have been produced and evaluated for therapy of various diseases, including …

Protein–polymer conjugates are widely used as therapeutics. All Food and Drug
Administration (FDA)-approved protein conjugates are covalently linked to poly (ethylene …

The high potential of peptides and proteins as therapeutic agents has not been fully
exploited because of their common shortcomings: the only exist for a short lifetime in the …

Pegylation is the most widely used and accepted methodology for half-life extension of
biopharmaceutical drugs that also improves physicochemical and biological characteristics …

Polyethylene glycol (PEG) is widely used as a covalent modifier of biological
macromolecules and particulates as well as a carrier for low molecular weight drugs. In the …